BioSpace News Archive

–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30

GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) --

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021 at 2:40 PM ET.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced topline results from its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA™

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences: 7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021 Fireside Chat: May 4, 1:50pm ET

The approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.

The primary cell culture market is estimated to observe promising growth on the back of the rising cases of autoimmune diseases, cancer, cardiovascular diseases, chronic conditions, diabetes, nephrological diseases, and others across the assessment period of 2020-2030.

The increasing demand for custom-made nucleotides for the required sequence through analysis, forensic applications, drug production, and genetic testing has resulted from the decreasing cost of sequencing.

Transparency Market Research has published a new report titled, “Life Science Instrumentation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.

According to a new TMR report, the benign prostatic hyperplasia treatment market is expected to grow at a robust 6% CAGR during 2019 to 2027.